Skip to main content
Clinical Trials/CTRI/2020/02/023589
CTRI/2020/02/023589
Recruiting
未知

COMPARATIVE STUDY OF LOW DOSE VERSUS STANDARD DOSE OF OLANZAPINE AS AN ADD-ON IN CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY - LONCIV

Sandip Mukhopadhyay0 sites100 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Sandip Mukhopadhyay
Enrollment
100
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Sandip Mukhopadhyay

Eligibility Criteria

Inclusion Criteria

  • 1\.Chemotherapy patients with age \>\= 18 years up to 80 years from both genders with histologically proven malignancy who have been offered high or moderately emetogenic chemotherapy.
  • 2\.Acceptable hepatic function (serum bilirubin \< 3mg/dl and transaminase \< 3X upper limit of normal).
  • 3\.Acceptable renal function (Serum creatinine \< 2mg/dl and/or Creatinine clearance \>\= 50ml/min).
  • 4\.No nausea in the previous 24 hours of starting the therapy.
  • 5\.Absolute neutrophil count \>1500/ dl
  • 6\.Education level at least 5th standard.
  • 7\.Life expectancy 4 months or more.

Exclusion Criteria

  • 1\.CNS disorders e.g. seizure, unstable brain metastasis.
  • 2\.Serious cardiac arrhythmia or dysfunction, congestive heart failure (CHF), recent myocardial infarction (MI).
  • 3\.Any uncontrolled severe concurrent illness or uncontrolled diabetes.
  • 4\.Gastric outlet obstruction, intestinal obstruction.
  • 5\.Vomiting within the last 24 hours before study drug administration.
  • 6\.Hypersensitivity to any of the study drugs.
  • 7\.Patients who received any cancer chemotherapy within the previous 3 weeks.
  • 8\.Patients who received any anti\-emetic, corticosteroid or any other drug that may influence the study within previous 24 hours.
  • 9\. Treatment with any antipsychotic drugs in previous 30 days of start of study,
  • 10\.Use of any other investigational drug and participation in any other study within 30 days of study enrollment.

Outcomes

Primary Outcomes

Not specified

Similar Trials